Related references
Note: Only part of the references are listed.Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
Fang Zhang et al.
JOURNAL OF EVIDENCE BASED MEDICINE (2022)
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study
Tomoe Kinoshita et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: a 1-yr randomized study
Marjorie Bastien et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2019)
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
Dehui Luo et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2018)
Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update
Marie-Eve Piche et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2018)
Cardiometabolic healthy obesity paradigm and all-cause mortality risk
Paul D. Loprinzi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Health Effects of Overweight and Obesity in 195 Countries over 25 Years
Ashkan Afshin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association Between Visceral and Subcutaneous Adipose Depots and Incident Cardiovascular Disease Risk Factors
Tobin M. Abraham et al.
CIRCULATION (2015)
Risk of Myocardial Infarction and Heart Failure Among Metabolically Healthy But Obese Individuals
Bjorn Morkedal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
PATHOPHYSIOLOGY OF HUMAN VISCERAL OBESITY: AN UPDATE
Andre Tchernof et al.
PHYSIOLOGICAL REVIEWS (2013)
Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial
Marshall J. Glesby et al.
PLOS ONE (2013)
Body Fat Distribution and Risk of Cardiovascular Disease An Update
Jean-Pierre Despres
CIRCULATION (2012)
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population
Wolfram Doehner et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
The Effect of Pioglitazone and Resistance Training on Body Composition in Older Men and Women Undergoing Hypocaloric Weight Loss
M. Kyla Shea et al.
OBESITY (2011)
Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes
Agnes Hartemann-Heurtier et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients
You-Cheol Hwang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Subcutaneous abdominal adipose tissue subcompartments: Potential role in rosiglitazone effects
Gillian E. Walker et al.
OBESITY (2008)
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity
Jaime L. Peters et al.
STATISTICS IN MEDICINE (2007)
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus
Tetsuya Teranishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Abdominal visceral and subcutaneous adipose tissue compartments - Association with metabolic risk factors in the Framingham Heart Study
Caroline S. Fox et al.
CIRCULATION (2007)
Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes
Ivana Zib et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2007)
Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome
Takuji Katayama et al.
AMERICAN HEART JOURNAL (2007)
Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss - An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
P Poirier et al.
CIRCULATION (2006)
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
SR Smith et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Molecular mediators of hepatic steatosis and liver injury
JD Browning et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes
P Iozzo et al.
DIABETES CARE (2003)
Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study
MB Snijder et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2003)
Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy
H Yki-Järvinen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects
KA Virtanen et al.
DIABETES (2003)
Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity
S Shadid et al.
DIABETES CARE (2003)
Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients
DG Carey et al.
OBESITY RESEARCH (2002)
Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation
T Albrektsen et al.
DIABETES (2002)
Association of visceral fat with coronary risk factors in a population-based sample of postmenopausal women
A Hernandez-Ono et al.
INTERNATIONAL JOURNAL OF OBESITY (2002)
Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - A randomized controlled trial
S Katoh et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Share Paper
